US5354772A
(en)
*
|
1982-11-22 |
1994-10-11 |
Sandoz Pharm. Corp. |
Indole analogs of mevalonolactone and derivatives thereof
|
US4613610A
(en)
*
|
1984-06-22 |
1986-09-23 |
Sandoz Pharmaceuticals Corp. |
Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
|
US5001255A
(en)
*
|
1984-12-04 |
1991-03-19 |
Sandoz Pharm. Corp. |
Idene analogs of mevalonolactone and derivatives thereof
|
JPS62501009A
(ja)
*
|
1984-12-04 |
1987-04-23 |
サンド・アクチエンゲゼルシヤフト |
メバロノラクトンのインデン同族体及びその誘導体
|
US4668794A
(en)
*
|
1985-05-22 |
1987-05-26 |
Sandoz Pharm. Corp. |
Intermediate imidazole acrolein analogs
|
KR900001212B1
(ko)
*
|
1985-10-25 |
1990-02-28 |
산도즈 파마슈티칼스 코오포레이숀 |
메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
|
US4851427A
(en)
*
|
1985-10-25 |
1989-07-25 |
Sandoz Pharm. Corp. |
Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
|
US4751235A
(en)
*
|
1986-12-23 |
1988-06-14 |
Sandoz Pharm. Corp. |
Anti-atherosclerotic indolizine derivatives
|
PT85662B
(pt)
*
|
1986-09-10 |
1990-06-29 |
Sandoz Sa |
Processo para a preparacao de derivados de aza-indol e de indolizina e de composicoes farmaceuticas que os contem
|
US4735958A
(en)
*
|
1986-12-22 |
1988-04-05 |
Warner-Lambert Company |
Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
|
US4897490A
(en)
*
|
1987-02-25 |
1990-01-30 |
Bristol-Meyers Company |
Antihypercholesterolemic tetrazole compounds
|
US4898949A
(en)
*
|
1987-02-25 |
1990-02-06 |
Bristol-Myers Company |
Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
|
US4894386A
(en)
*
|
1987-04-15 |
1990-01-16 |
Ici Americas Inc. |
Aliphatic carboxamides
|
US4904646A
(en)
*
|
1987-05-22 |
1990-02-27 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing HMG-COA reductase inhibitors
|
US5091378A
(en)
*
|
1987-05-22 |
1992-02-25 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
|
CA1336714C
(en)
*
|
1987-08-20 |
1995-08-15 |
Yoshihiro Fujikawa |
Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
|
US5185328A
(en)
*
|
1987-08-20 |
1993-02-09 |
Nissan Chemical Industries Ltd. |
Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
|
JP2569746B2
(ja)
*
|
1987-08-20 |
1997-01-08 |
日産化学工業株式会社 |
キノリン系メバロノラクトン類
|
DE3739882A1
(de)
*
|
1987-11-25 |
1989-06-08 |
Bayer Ag |
Substituierte hydroxylamine
|
US4868185A
(en)
*
|
1987-12-10 |
1989-09-19 |
Warner-Lambert Company |
6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
|
HU202842B
(en)
*
|
1988-01-27 |
1991-04-29 |
May & Baker Ltd |
Process for producing new isoquinolinone derivatives and pharmaceutical compositions containing them
|
US4822799A
(en)
*
|
1988-01-27 |
1989-04-18 |
Sandoz Pharm. Corp. |
Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
|
NO890522L
(no)
*
|
1988-02-25 |
1989-08-28 |
Bayer Ag |
Substituerte imidazolinoner og imidazolinthioner.
|
JP2890448B2
(ja)
*
|
1988-04-26 |
1999-05-17 |
日産化学工業株式会社 |
ピラゾロピリジン系メバロノラクトン類
|
US5024999A
(en)
*
|
1988-04-26 |
1991-06-18 |
Nissan Chemical Industries Ltd. |
Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
|
US5010205A
(en)
*
|
1988-08-23 |
1991-04-23 |
Bristol-Myers Company |
Antihypercholesterolemic tetrazol-1-yl intermediates
|
US4870187A
(en)
*
|
1988-08-23 |
1989-09-26 |
Bristol-Myers Company |
Antihypercholesterolemic tetrazol-1-yl compounds
|
NZ230121A
(en)
*
|
1988-08-29 |
1993-08-26 |
Squibb & Sons Inc |
Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
|
US5506219A
(en)
*
|
1988-08-29 |
1996-04-09 |
E. R. Squibb & Sons, Inc. |
Pyridine anchors for HMG-CoA reductase inhibitors
|
SG139553A1
(en)
*
|
1988-10-13 |
2008-02-29 |
Novartis Ag |
7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof
|
JPH04270285A
(ja)
*
|
1988-11-14 |
1992-09-25 |
Nissan Chem Ind Ltd |
ピラゾロピリミジン系メバロノラクトン類
|
DE3911064A1
(de)
*
|
1989-04-06 |
1990-10-11 |
Bayer Ag |
Substituierte 1,8-naphthyridine
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
GB8919091D0
(en)
*
|
1989-08-22 |
1989-10-04 |
Fujisawa Pharmaceutical Co |
Pyrroloquinoline compounds
|
IT1237792B
(it)
*
|
1989-12-21 |
1993-06-17 |
Zambon Spa |
Composti attivi come inibitori dell'enzima hmg-coa reduttasi
|
HU217629B
(hu)
*
|
1991-12-12 |
2000-03-28 |
Novartis Ag. |
Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
|
DE4243279A1
(de)
|
1992-12-21 |
1994-06-23 |
Bayer Ag |
Substituierte Triole
|
JP2736599B2
(ja)
*
|
1993-07-23 |
1998-04-02 |
株式会社キッツ |
ボールバルブのシート構造
|
US6425881B1
(en)
|
1994-10-05 |
2002-07-30 |
Nitrosystems, Inc. |
Therapeutic mixture useful in inhibiting lesion formation after vascular injury
|
DE69719755T2
(de)
*
|
1996-06-24 |
2003-11-20 |
Novartis Ag |
Polymorphe verbindungen
|
WO1998055454A2
(en)
|
1997-06-05 |
1998-12-10 |
Takeda Chemical Industries, Ltd. |
Benzofurans and benzothophenes as suppressors of neurodegeneration
|
KR20010073232A
(ko)
|
1998-11-20 |
2001-07-31 |
추후제출 |
분산성 인지질로 안정화된 마이크로입자
|
US6242003B1
(en)
|
2000-04-13 |
2001-06-05 |
Novartis Ag |
Organic compounds
|
CN1217930C
(zh)
|
2000-05-26 |
2005-09-07 |
西巴特殊化学品控股有限公司 |
吲哚衍生物的制备方法和该方法的中间体
|
US20060127474A1
(en)
|
2001-04-11 |
2006-06-15 |
Oskar Kalb |
Pharmaceutical compositions comprising fluvastatin
|
KR20040018359A
(ko)
|
2001-04-18 |
2004-03-03 |
젠자임 코포레이션 |
지방족 폴리아민으로 x 증후군을 치료하는 방법
|
ES2304140T3
(es)
*
|
2001-08-03 |
2008-09-16 |
Ciba Holding Inc. |
Formas cristalinas de sodio de fluvastatina.
|
WO2003060078A2
(en)
|
2001-12-21 |
2003-07-24 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
WO2003086395A1
(en)
|
2002-04-12 |
2003-10-23 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US7312353B2
(en)
|
2003-08-21 |
2007-12-25 |
Merck Frost Canada & Co. |
Cathespin cysteine protease inhibitors
|
EP1510208A1
(en)
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Pharmaceutical composition comprising a combination of metformin and statin
|
CN100404479C
(zh)
*
|
2003-08-27 |
2008-07-23 |
住友化学株式会社 |
芳族不饱和化合物的制备方法
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
US7709508B2
(en)
|
2004-12-09 |
2010-05-04 |
Merck Sharp & Dohme |
Estrogen receptor modulators
|
JP2008523065A
(ja)
*
|
2004-12-09 |
2008-07-03 |
メルク エンド カムパニー インコーポレーテッド |
エストロゲン受容体モジュレーター
|
EP2783687A1
(en)
|
2005-03-02 |
2014-10-01 |
Merck Sharp & Dohme Corp. |
Composition for inhibition of cathepsin K
|
CA2613517A1
(en)
|
2005-06-27 |
2007-01-04 |
Exelixis, Inc. |
Pyrazole based lxr modulators
|
WO2007017117A1
(en)
*
|
2005-07-28 |
2007-02-15 |
Lek Pharmaceuticals D.D. |
Process for the synthesis of rosuvastatin calcium
|
US8440695B2
(en)
|
2005-11-09 |
2013-05-14 |
St Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
WO2007121484A2
(en)
|
2006-04-19 |
2007-10-25 |
Novartis Ag |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
DE602006006899D1
(de)
|
2006-04-20 |
2009-07-02 |
Italiana Sint Spa |
Verfahren zur Herstellung von Fluvastatin-Natrium
|
KR101433394B1
(ko)
|
2006-07-05 |
2014-08-26 |
다케다 게엠베하 |
염증성 폐질환의 치료를 위한 HMG-CoA 리덕타제 억제제와 포스포디에스터라제 4 억제제의 병용
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
JP5330274B2
(ja)
|
2007-03-01 |
2013-10-30 |
ノバルティス アーゲー |
Pimキナーゼ阻害剤およびその使用方法
|
EP2152700B1
(en)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r inhibitors, compositions, and methods of use
|
ES2330184B1
(es)
|
2008-06-03 |
2010-07-05 |
Neuron Biopharma, S.A. |
Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
|
EP2327682A1
(en)
|
2009-10-29 |
2011-06-01 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
SI2373609T1
(sl)
|
2008-12-19 |
2013-12-31 |
Krka, D.D., Novo Mesto |
Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
|
SG176247A1
(en)
|
2009-05-28 |
2012-01-30 |
Bristol Myers Squibb Co |
Lxr modulators
|
JP6073677B2
(ja)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
縮合複素環式化合物およびそれらの使用
|
EP2937345B1
(en)
|
2009-12-29 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
WO2011115725A2
(en)
|
2010-03-16 |
2011-09-22 |
Dana-Farber Cancer Institute, Inc. |
Indazole compounds and their uses
|
US8372877B2
(en)
|
2010-04-16 |
2013-02-12 |
Cumberland Pharmaceuticals |
Stabilized statin formulations
|
US20130210860A1
(en)
|
2010-10-06 |
2013-08-15 |
Kowa Co., Ltd. |
Prophylactic and/or therapeutic agent against lymphedema
|
WO2012112363A1
(en)
|
2011-02-14 |
2012-08-23 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
TW201242953A
(en)
|
2011-03-25 |
2012-11-01 |
Bristol Myers Squibb Co |
Imidazole prodrug LXR modulators
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
KR20140108705A
(ko)
|
2011-12-29 |
2014-09-12 |
트러스티즈 오브 터프츠 칼리지 |
재생 및 염증 반응을 제어하기 위한 생체물질의 기능화
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
CN105209039B
(zh)
|
2013-03-15 |
2018-06-22 |
百时美施贵宝公司 |
Lxr调节剂
|
EP2810644A1
(en)
|
2013-06-06 |
2014-12-10 |
Ferrer Internacional, S.A. |
Oral formulation for the treatment of cardiovascular diseases
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
CA2923272A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
AU2016243529B2
(en)
|
2015-03-27 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
AU2016319125B2
(en)
|
2015-09-09 |
2021-04-08 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|